Information for the public
About this information
This information explains the evidence summary about the off-label use of a lower dose than normal of bevacizumab as first-line treatment for advanced ovarian cancer. The evidence summary is an overview of the available information about this medicine. It aims to help prescribers and patients when they are considering whether or not to use an unlicensed or off-label treatment. The summary does not contain recommendations from NICE on whether the medicine should be used at this lower dose for advanced ovarian cancer. NICE has looked at bevacizumab when used at the higher recommended dose with paclitaxel and carboplatin as first-line treatment for advanced ovarian cancer and does not recommend it.